Compare Amphastar Pharmaceuticals Inc (AMPH) vs IONQ Inc (IONQ) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

IONQ stock trades at $44.43, up 11.86% in 24 hours, with a bullish technical signal and strong revenue growth of 287% year-over-year in Q2 2026. The company reported a Q2 EPS miss but revenue beat, raised its 2026 outlook, and secured a $28 million defense contract. Valuation ratios are elevated with a P/E of 102.38 and P/S of 59.02, while profitability remains negative with a net income margin of -553.27% in 2026.

Outlook is optimistic due to quantum computing demand and analyst consensus price target of $73.33, but risks include high cash burn, intense competition, and reliance on speculative technology. Investors should weigh growth potential against persistent losses and dilution concerns from recent share issuance.